TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04281134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Summit RC+S System
Description: Summit RC+S System consists of:~(i) One Model B35300R Olympus RC+S neurostimulator; (ii) One Model 4NR009 Patient Therapy Manager; (iii) One Model 4NR011 Clinician Telemetry Module; (iv) Two Model 3387 DBS leads; (v) Two Model 37087-60 DBS extensions; and (vi) One Model 97755 Recharger.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One Month Blinded Discontinuation Period:
Description: The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline.
Study: NCT02123251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: This intervention will examine the effects of incentives on improving adult diabetic Medicaid beneficiaries' health outcomes and reducing associated costs through healthy behavior changes in their diabetes self-management. Incentives focus on improving self-management of diabetes, compliance with ADA recommended preventive, treatment and management measures, primary biometric measures of diabetes, and eliminating barriers to a healthy lifestyle
Study: NCT01343641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0677
Description: The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79. It is produced by Merck \& Co, Inc.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Pill used as a comparator
Study: NCT00264758

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional hemodialysis
Description: Three times per week in-center hemodialysis
Study: NCT00486278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatreptacog alfa (activated)
Description: 20 mcg/kg, injected i.v.
Study: NCT00264758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis
Description: Six times per week in-center hemodialysis
Study: NCT02975232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: F&V economic incentive
Description: 50% off eligible fresh, frozen and canned fruits and vegetables (up to $10/day)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooking Matters Store Tour
Description: Participants will be asked to attend one Coking Matters store tour during January or February 2017
Study: NCT01368224

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei NCC 2461 and Bifidobacterium longum NCC3001
Description: 1 treatment unit, in the form of a sachet of powder, to be reconstituted in a glass of water and taken once daily for 8 weeks (from D1 to D57), except if the last visit is bring forward or put back for no more than 3 days, in which case the subject will continue treatment until the final visit.~Oral route.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei NCC 2461 and Bifidobacterium longum NCC3001
Description: 1 treatment unit, in the form of a sachet of powder, to be reconstituted in a glass of water and taken once daily for 8 weeks (from D1 to D57), except if the last visit is bring forward or put back for no more than 3 days, in which case the subject will continue treatment until the final visit.~Oral route.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus paracasei NCC 2461 and Bifidobacterium longum NCC3001
Description: 1 treatment unit, in the form of a sachet of powder, to be reconstituted in a glass of water and taken once daily for 8 weeks (from D1 to D57), except if the last visit is bring forward or put back for no more than 3 days, in which case the subject will continue treatment until the final visit.~Oral route.
Study: NCT03820700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis (Hypn)
Description: The hypnosis session will consist of a 20-minute hypnosis recording created by Marie-Elisabeth Faymonville and recorded by Anne-Sophie Nyssen, both professionals in hypnosis from University of Liège. The recording includes suggestions about relaxation, corporal sensations, respiratory techniques and visual imaginative stimuli about a beautiful landscape. With this tool, the hypnosis session is standardized for all patients and there is no need of a psychotherapist to deliver hypnosis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR)
Description: VR sessions. This session will consist in using a head-mounted 3D graphical display with goggles. With this tool, participants will be able to visualize a 3D immersive landscape for 20 minutes consisting of a shed near a lake at sunrise followed by a relaxing moment in the clouds. The session ends on the lake's edge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality hypnosis (VRH)
Description: The combined tool sessions. Participants will be simultaneously subjected to the same hypnosis recording and 3D visual stimuli used in the Hypn and VR conditions.
Study: NCT03209739

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WhatsApp reminder
Description: An additional WhatsApp reminder with same content of the written instruction and a video of explanation of bowel preparation by a nurse 4 days prior colonoscopy
Study: NCT02491944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Single oral dose of 80 mg AZD9291 tablet on Day 1 administered orally with 240 mL water following an overnight fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]AZD9291
Description: Each healthy male subject will also receive a single, radiolabeled, 100 μg dose of \[14C\] AZD9291 administered as an IV microdose infusion starting at 5 hours and 45 minutes after receiving the oral dose.
Study: NCT03930264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine 50Mg Tab
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine 10mg/mL oral suspension
Description: oral suspension
Study: NCT03406091

Intervention type: DRUG
Intervention: Plerixafor
Description: Plerixafor (AMD3100) is a selective, reversible inhibitor of the receptor chemokine (C-X-C motif) receptor 4 (CXCR4) and prevents binding of its cognate ligand stromal cell derived factor-1α (SDF-1α), also known as chemokine (C-X-C motif) ligand 12 (CXCL12) \[3\]. CXCR4 is a co-receptor, along with CD4, for the binding of human immunodeficiency virus, type 1 (HIV-1) to its receptor cells.
Study: NCT01030081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine (Norvasc®)
Description: Amlodipine (Norvasc®), tablet, 5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine GITS (Adalat® XL 30
Description: Nifedipine GITS (Adalat® XL 30), controlled released tablet, 30 mg
Study: NCT00771862

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: perineural ropivicaine
Description: Subjects will be randomized to one of two groups: ropivicaine 0.2% infusion for days 0-1 then infusion with normal saline (placebo) for days 1 through catheter removal (POD 4 or 5) or ropivicaine 0.4% infusion for day 0 through catheter removal (POD 4 or 5). The infusion rate will be set at 7-11 mL/h.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perineural ropivicaine
Description: Subjects will be randomized to one of two groups: ropivicaine 0.2% infusion for days 0-1 then infusion with normal saline (placebo) for days 1 through catheter removal (POD 4 or 5) or ropivicaine 0.4% infusion for day 0 through catheter removal (POD 4 or 5). The infusion rate will be set at 7-11 mL/h.
Study: NCT04546984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC96719
Description: Part 2：Mulltiple doses up to 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC96719
Description: Part 2：Mulltiple doses up to 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC96719
Description: Part 2：Mulltiple doses up to 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC96719
Description: Part 2：Mulltiple doses up to 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC96719
Description: Part 2：Mulltiple doses up to 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC96719
Description: Part 2：Mulltiple doses up to 10 days
Study: NCT00486278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatreptacog alfa (activated)
Description: 40 mcg/kg, injected i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatreptacog alfa (activated)
Description: 80 mcg/kg, injected i.v.
Study: NCT05420389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breast massage
Description: Mothers who were included in the breast massage group who met the research criteria were informed about the use of milking pumps in the routine application of the hospital and the condition anxiety scale was filled out on the first day. These mothers were shown breast massage during the use of milking pumps, they were provided with their own application and a brochure was given explaining the application.As long as the breast milk follow-up form to record the amounts of milk they milked was in the hospital, the researcher explained how to fill it out when discharged and was asked to fill out the last-day conditional anxiety scale (SATI-I). Milk amounts are measured in ml.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hot compress
Description: Mothers who were included in the hot application group were informed about the use of milking pumps in the routine application of the hospital and the condition anxiety scale (STAI-I) was filled out on the first day. These mothers were shown the hot application they would make during the use of milking pumps, they were provided with the application and a brochure was given explaining the application.The hot chest compress to be used in this group will be used in the Lansinoh brand Thera°Pearl® Hot Breast Therapy pad, which is sold in medical medicines in pharmacies approved by the Ministry of Health.The breast milk follow-up form, in which they will record the amounts of milk they milk, was explained by the researcher in the hospital and how to fill it out when they were discharged, and they were asked to fill out a last-day anxiety scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breast massage-hot compress
Description: Mothers who were included in the breast massage and hot application group were informed about the use of milking pumps in the routine application of the hospital, the data collection form and the condition anxiety scale were filled out on the first day. These mothers were shown breast massage and hot application during the use of milking pumps, they were provided with their own application and a brochure was given explaining the application.As long as the breast milk follow-up form to record the amounts of milk they milked was in the hospital, the researcher explained how to fill it out when discharged and was asked to fill out the last-day conditional anxiety scale (SATI-I). Milk amounts are measured in ml.
Study: NCT00466310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole for 4 weeks
Study: NCT03488511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FoodforCare at home
Description: Six small protein rich meals that will be delivered twice a week for 3 weeks.
Study: NCT00223782

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Gait Training with Feedback

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Gait Training with no feedback
Study: NCT02452827

Intervention type: OTHER
Intervention: Biomechanical parameters

Intervention type: OTHER
Intervention: Biomechanical parameters

Intervention type: OTHER
Intervention: MRI
Description: MRI of cervical spine

Intervention type: OTHER
Intervention: MRI
Description: MRI of cervical spine
Study: NCT01624311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: After obtaining written consent, patients are cooled to 33.5°C (+/- 1°C ) for 72 hours and and then rewarmed by 0.5°C per every 3 hours over 18 hours.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Therapy
Description: Patients with hyperammonemia and encephalopathy requiring renal replacement therapy due to a urea cycle disorder or organic acidemia that were treated at Children's National Medical Center over the past 10 years.
Study: NCT02338882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi flex M multifocal intraocular lens
Description: Multifocal intraocular lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bi flex 1.8 monofocal intraocular lens
Description: Standard monofocal intraocular lens
Study: NCT00505778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine Once-Daily
Description: Mesalamine tablets, 1.6-2.4 g/day taken orally once a day for 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine Twice-Daily
Description: Mesalamine tablets, 1.6-2.4 g/day, taken twice daily for 52 weeks
Study: NCT01024621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomicroscope
Description: Pentax EC3870K, Tokyo, Japan

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard endoscopy
Description: Pentax EG-2931 gastroscope
Study: NCT02384915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prilocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mepivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic-femoral Nerve Block
Description: ultrasound-guided 25 ml 2% mepivacaine injection on both femoral and sciatic nerve

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: intrathecal injection of 40 mg hyperbaric prilocaine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sonoplex, Pajunk
Study: NCT04466579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BIS monitor
Description: BIS monitor is used to control and monitor the depth of general anesthesia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard anesthesiology care according to the protocol of the study
Study: NCT03663660

Intervention type: OTHER
Intervention: Organizational infrastructure pediatric plan (OIPP)
Description: Restructuration of the hospital sectors with a stratification of health care into 4 levels.
Study: NCT03049241

Intervention type: OTHER
Intervention: neuromuscular fatigue
Description: The main aim of the present protocol is to compare the effect of knee extensors and ankle plantarflexors length on the development and aetiology of neuromuscular fatigue, in children and adults

Intervention type: OTHER
Intervention: neuromuscular fatigue
Description: The main aim of the present protocol is to compare the effect of knee extensors and ankle plantarflexors length on the development and aetiology of neuromuscular fatigue, in children and adults
Study: NCT02686723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical and biomechanical evaluations
Description: Clinical evaluation : demographics, clinic and functional testing. Biomechanical evaluation : isokinetic, motion analysis of 2 specific motion (drop vertical jump and cutting task) and anterior tibial translation with GnRB

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical and biomechanical evaluations
Description: Clinical evaluation : demographics, clinic and functional testing. Biomechanical evaluation : isokinetic, motion analysis of 2 specific motion (drop vertical jump and cutting task) and anterior tibial translation with GnRB
Study: NCT01446783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mecasermin
Description: 0,1 ml mecasermin (10 mg/ml) is injected intratendinous into the patella tendon with ultrasound guidance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mecasermin
Description: 0,1 ml mecasermin (10 mg/ml) is injected intratendinous into the patella tendon with ultrasound guidance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0,1 ml saline is injected intratendinous into the patella tendon with ultrasound guidance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0,1 ml saline is injected intratendinous into the patella tendon with ultrasound guidance.
Study: NCT00466310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Subjects will be randomized to risperidone for 4 weeks
Study: NCT02129504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: root coverage comparing two techniques
Description: The aim of this study was to compare and show the benefits of the extended flap technique (new technique) compared to coronal advanced technique (gold standard technique) both techniques using the porcine collagen matrix for root coverage.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: root coverage comparing two techniques
Description: The aim of this study was to compare and show the benefits of the extended flap technique (new technique) compared to coronal advanced technique (gold standard technique) both techniques using the porcine collagen matrix for root coverage.
Study: NCT01012219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niacin (+) laropiprant
Description: open-label, single dose Tredaptive (1000mg ER niacin/ 20mg laropiprant) 2 oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: aspirin
Description: 81 mg oral tablet once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: aspirin
Description: 81 mg oral tablet once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: clopidogrel
Description: 75 mg oral tablet once daily for 7 days
Study: NCT00466310

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy volunteers
Description: Healthy volunteers
Study: NCT04275115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Cocktail
Description: Single oral dose of the cocktail probe substrates (caffeine 200 mg, montelukast 10 mg, midazolam 4 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foliglurax
Description: Foliglurax

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam iv
Description: Single intravenous (iv) dose of midazolam 0.025 mg/kg
Study: NCT02183519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: For reflex cough testing, all participants will receive various concentrations of nebulized capsaicin. Delivery of multiple concentrations and doses of capsaicin allows for accurate assessment of both the strength (airflow measures) of reflex, as well as cough sensitivity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: For reflex cough testing, all participants will receive various concentrations of nebulized capsaicin. Delivery of multiple concentrations and doses of capsaicin allows for accurate assessment of both the strength (airflow measures) of reflex, as well as cough sensitivity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voluntary cough test
Description: Participants will be fitted with a facemask covering their mouth and nose, and instructed to cough into the facemask.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voluntary cough test
Description: Participants will be fitted with a facemask covering their mouth and nose, and instructed to cough into the facemask.
Study: NCT04291755

Intervention type: DRUG
Intervention: Pembrolizumab Injection
Description: Any checkpoint inhibitor is acceptable
Study: NCT03961360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg
Description: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 162 mg
Description: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia
Study: NCT03863626

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frusemide IV shots
Description: giving frusemide by IV shots~And if developed diuretic resistance (diminishing diuretic effect despite incremental dose of IV loop diuretic), adjuvant oral Metolazone will be given for sequential nephron blockade comparing its administration timed 60 minutes prior to the morning Frusemide shot versus given after. (This will be in a second level of randomization)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frusemide IV infusion
Description: giving frusemide by continuous IV infusion~And if developed diuretic resistance (diminishing diuretic effect despite incremental dose of IV loop diuretic), adjuvant oral Metolazone will be given for sequential nephron blockade
Study: NCT03757104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: micro-incentive
Description: Residents in these communities are eligible to receive a R50 food voucher conditional on undergoing a home-based HIV test. If diagnosed with HIV, residents are eligible to receive a second R50 food voucher when they link to care within 6 weeks of the HIV test
Study: NCT01012219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: clopidogrel
Description: 75 mg oral tablet once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: laropiprant
Description: 40 mg oral tablet once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: laropiprant
Description: 40 mg oral tablet once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Description: placebo oral tablet once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Description: placebo oral tablet once daily for 7 days